Yang Che-Hsueh, Ou Yen-Chuan, Lin Chi-Chien, Lin Yi-Sheng, Tung Min-Che, Yu Chia-Cheng, Lin Jen-Tai, Wen Chen-Yueh
Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung 435, Taiwan.
Institute of Biomedical Science, The iEGG and Animal Biotechnology Center, National Chung-Hsing University, Taichung 402, Taiwan.
Life (Basel). 2022 Jul 11;12(7):1029. doi: 10.3390/life12071029.
Currently, medication for benign prostate hyperplasia (BPH) and prostate cancer (PCa) are mainly based on modulating the hormone and nervous systems. However, side effects often affect patients, and might decrease their commitment to continuing the medication and lower their quality of life. Some studies have indicated that chronic inflammation might be the cause of BPH and PCa. Based on this hypothesis, the effect of phloretin, a potent anti-inflammatory and anti-oxidative flavonoid, has been researched since 2010. Results from animal and in-vitro studies, obtained from databases, also indicate that the use of phloretin in treating BPH and PCa is promising. Due to its effect on inflammatory cytokines, apoptosis or anti-apoptosis, reactive oxygen species, anti-oxidant enzymes and oxidative stress, phloretin is worthy of further study in human clinical trials regarding safety and effective dosages.
目前，用于治疗良性前列腺增生（BPH）和前列腺癌（PCa）的药物主要基于调节激素和神经系统。然而，副作用常常影响患者，可能会降低他们持续用药的依从性并降低其生活质量。一些研究表明，慢性炎症可能是BPH和PCa的病因。基于这一假设，自2010年以来，人们对根皮素（一种有效的抗炎和抗氧化类黄酮）的作用进行了研究。从数据库中获取的动物和体外研究结果也表明，根皮素用于治疗BPH和PCa具有前景。由于其对炎性细胞因子、细胞凋亡或抗细胞凋亡、活性氧、抗氧化酶和氧化应激的作用，根皮素在安全性和有效剂量方面值得在人体临床试验中进一步研究。
